New research suggests that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who stop conventional lifestyle regimens.
Published data in a major health publication demonstrates that while overweight people can lose substantial amounts of their total mass while undergoing treatment, the mass is regained at an estimated rate of 0.8 kg per month once they quit.
"Users purchasing these treatments need to be cognizant of the danger of quick rebound weight gain when the therapy ends," cautioned expert Dr. Susan Jebb.
Such speed of regain means a return to original mass within about 18 months.
Weighing Treatments
The study, which reviewed dozens of studies involving over 9,000 of participants, compared the effects of GLP-1 agonists with other pills.
Researchers note that individuals who shed pounds through diet and exercise generally see a more gradual creep back—perhaps 0.1 kg a month—after stopping.
The Reason for the Rapid Rebound
Doctors propose the mechanism of the injections accounts for the accelerated regain.
These medications copy a natural hormone called glucagon-like peptide-1, which controls appetite.
"Long-term administration of the hormone concentrations far above than the body's typical production may cause the system to generate a reduced amount of its own natural GLP-1, and may also diminish sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert.
"Stopping of this medication leads to hunger is uncontrolled, making overeating far more likely."
An Ongoing Issue?
Medical guidelines recommend the injections for people with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians argue that, considering the significant potential of weight regain, the therapy is often life-long.
This opinion is echoed by drug manufacturers, who state that the findings "highlight the persistent nature of obesity," akin to managing diseases like hypertension.
User Experiences
Users who have stopped the medication report a sudden resurgence of appetite.
"I experienced something flipping and you're instantly starving," said one woman.
This challenge is exacerbated if users have not adopted permanent lifestyle or habit changes during therapy.
Significant Adoption
Figures indicate that a significant number of adults in the UK have used these injections in the last 12 months, with interest continuing to grow.
- Use is higher among females than males.
- The 40s and 50s age group shows the highest level of interest.
- Many access the drugs through private prescriptions rather than the NHS.
In conclusion, experts caution that while these medications are powerful tools for weight loss, they are not a standalone fix and maintained weight loss hinges on integrated behavioural management.
